Registry follows patients with upper tract urothelial cancer treated with Jelmyto
Records real-world outcomes of adults with upper tract urothelial cancer treated with Jelmyto.
Plain-language title generated from the registry record
Registry title: uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Key facts
- Where
- Ann Arbor, Baltimore, Boston, Chapel Hill, Chicago, Columbia, Columbus, Dallas, Gainesville, Houston, Indianapolis, Iowa City, Lake Success, Miami, Nashville, New Brunswick, New York, Santa Monica, Syracuse, and Tampa, United StatesSee the 22 sites
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- Chesapeake UrologyBaltimore, United StatesTaking people
- Johns Hopkins Medical CenterBaltimore, United StatesTaking people
- Brigham and Women's HospitalBoston, United StatesTaking people
- Mass General BrighamBoston, United StatesTaking people
- The University of North Carolina Chapel HillChapel Hill, United StatesTaking people
- Northwestern UniversityChicago, United StatesTaking people
- University of MissouriColumbia, United StatesTaking people
- Ohio State UniversityColumbus, United StatesTaking people
- UT Southwestern Medical CenterDallas, United StatesTaking people
- University of FloridaGainesville, United StatesTaking people
- The University of Texas M. D. Anderson Cancer CenterHouston, United StatesTaking people
- Indiana UniversityIndianapolis, United StatesTaking people
- The State University of IowaIowa City, United StatesTaking people
- The Feinstein Institutes for Medical ResearchLake Success, United StatesTaking people
- Mount Sinai Medical Center of Florida, Inc.Miami, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- RutgersNew Brunswick, United StatesTaking people
- NYU Grossman School of MedicineNew York, United StatesTaking people
- Providence St. Johns Health CenterSanta Monica, United StatesTaking people
- SUNY UpstateSyracuse, United StatesTaking people
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.Tampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UroGen Pharma Ltd.
- Trial code
- NCT05874921
- Record updated
- 29 September 2026
- Original description
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.Read full original descriptionShow less
uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Inclusion: Adults >18 years old and capable of giving informed consent; Diagnosis of UTUC; Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).
Exclusion: Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia); Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture); Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020); Pregnancy or lactation; Unable to comply with protocol requirements (for prospective data capture).